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ABSTRACT
The CD45 antigen is present on all cells of the hematopoietic lineage. In some rodent models, lytic CD45
monoclonal antibodies (MAbs) induce complete marrow aplasia. In others, only transient myelolymphodeple-
tion are observed, which are nonetheless sufficient to permit engraftment with fully allogeneic stem cells after
otherwise ineffective doses of radiation. The in vivo effects of unconjugated cytolytic CD45 MAbs on myeloid
and lymphoid cells in humans are unknown, so it is unclear if they could contribute in a similar way to
conventional ablative or to nonmyeloablative preparative regimens used for stem cell transplantation (SCT).
We therefore assessed the safety, myeloreductive activities, and lymphoreductive activities of the unconjugated
rat anti-human CD45 MAbs, YTH25.4 and YTH54.12, in subjects who were to undergo SCT for advanced
hematologic malignancy. The MAb pair bind to contiguous but nonoverlapping epitopes on CD45 and work
synergistically to fix complement and recruit cellular lytic mechanisms. The MAbs were given in increasing
doses up to 1600 g/kg during 4 days, after which the patients began their conventional transplantation
preparative regimen. The maximum tolerated dose of these MAbs, 400 g/kg/d, produced marked reduction
in circulating lymphoid and myeloid cells while largely sparing marrow progenitors. In 2 of 3 patients who had
active leukemia at the time of study, the MAbs reduced the percentage of leukemic blast cells in bone marrow.
Seven of 14 patients are disease free 610 to 1555 days post-SCT. The in vivo myeloreductive and lymphore-
ductive properties of lytic CD45 MAb in humans, therefore, closely parallel the activity seen in a murine model
and, therefore, may be of similar value.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Conventional allogeneic stem cell transplantation
(SCT) requires high doses of drugs and/or radiation to
produce sufﬁcient host stem cell and immune system
ablation to permit donor stem cell engraftment. Dur-
ing the past few years, it has proved possible to greatly
reduce the intensity of conditioning regimens and
perform “nonmyeloablative” transplantation in which
host immunosuppression allows engraftment of a do-
nor immune system and progressive replacement of
host with donor hemopoiesis [1-3]. If the full potential
of SCT is to be achieved, particularly for nonmalig-
nant disease, these preparative regimens will need to
be made as effective and as safe as possible. Monoclo-
nal antibodies (MAbs) afford one means by which
highly speciﬁc and effective depletion of host immune
and hemopoietic systems can be obtained before
transplantation with donor stem cells.
A particularly attractive target antigen for these
MAbs is CD45, the common leukocyte antigen ex-
pressed by almost all nucleated white blood cells
(WBCs), including T cells, natural killer (NK) cells,
and granulocytes [4-7]. Almost all hematologic malig-
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nancies also express high levels of the antigen, poten-
tially allowing intensiﬁcation of pretransplantation an-
tileukemic therapy without an associated increase in
nonspeciﬁc toxicity. CD45 MAbs conjugated to a ra-
dionuclide already have been used in both animal
models of leukemia and in human disease [8,9]. Al-
though this approach has proved promising and ap-
pears to improve disease-free survival following SCT,
the delivery of a substantial dose of radiation to some
tissues can cause hypothyroidism and interstitial pneu-
monia in a signiﬁcant proportion of patients [8]. Un-
conjugated anti-CD45 antibodies capable of recruit-
ing host lytic effector mechanisms may be an
alternative to the hazards of radioisotope use, specif-
ically sparing normal tissue from radiation. These
unconjugated antibodies may induce target cell de-
struction through any combination of antibody-de-
pendent cellular cytotoxicity, complement-mediated
lysis, and opsonization and phagocytosis [10,11].
In rats, lytic CD45 MAbs have produced complete
marrow aplasia and death in the absence of stem cell
rescue [12]. In mice, however, a lytic CD45 MAb
produced leucodepletion without marrow ablation,
even when saturating MAb doses were used [13]. Al-
though there was rapid spontaneous recovery of he-
mopoiesis, T-cell, NK cell, and B-cell numbers all
were profoundly reduced. These nonmyeloablated
mice could successfully be engrafted with fully H2
allogeneic stem cells, becoming complete hemopoietic
chimeras with the addition of an otherwise ineffective
dose of radiation.
These promising animal data led us to investigate
the effects of lytic CD45 MAb given to patients who
were to undergo an allogeneic SCT for advanced
hematologic malignancy. We used two unconjugated
rat antihuman CD45 MAbs, YTH54.12 and
YTH25.4, which are of the IgG2b subclass, bind to
noncompeting but proximate CD45 epitopes present
on all CD45 isoforms, and, in combination, have a
synergistic ability to lyse human hematopoietic and
lymphoid cells by complement-mediated and cell-de-
pendent mechanisms [14]. We used this clinical study
to determine the safety of these highly lytic MAbs in
vivo and to discover whether, in tolerated doses, they
produced the stem cell ablation observed in the rat
model or the more limited myeloreduction observed
in mice. We also examined their effects on the T- and
NK cell populations because these components of
the immune system are critical in mediating graft
rejection. Our results indicate that the in vivo myelo-
reductive and lymphoreductive properties of lytic
CD45 MAb in humans closely parallel the non-
myeloablative activity seen in a murine model and,
therfore, may be of similar value to facilitate stem cell
engraftment.
PATIENTS, MATERIALS, AND METHODS
Study Description
The Institutional Review Board and Food and Drug
Administation approved this study for patient enroll-
ment, and all patients or their legal guardian signed the
approved consent form. Any patient with a diagnosis of
relapsed or resistant leukemia or myelodysplastic disease
was eligible for treatment. Eligibility also required that
CD45 be expressed on 95% of malignant cells.
The dose of CD45 MAb was doubled each day of
treatment and the starting dose was increased after a
minimum of 3 patients were treated without signiﬁ-
cant toxicity (Table 1). Dose escalation was permitted
provided that no grade III or IV nonhematologic
toxicity was induced. The CD45 MAbs starting dose
of 6.25 g/kg was chosen because it was considered to
be too low to produce immediate biological effects,
which, based on experimental data, were expected at
plasma levels of 25 g/L or greater [14].
Characteristics of the Patients
In this phase I study, we enrolled 14 patients with
leukemia (Table 2) with a median age of 3.8 years
(range, 0.6-18.1 years). Their diagnoses were acute
lymphoblastic leukemia (ALL, n  5), acute myeloid
leukemia (AML, n  4), undifferentiated acute leuke-
mia (AUL, n  1), and myelodysplastic syndrome
(MDS, n  4), including a case of juvenile my-
elomonocytic leukemia. All patients had advanced or
high-risk disease (Table 2).
Phenotypic Analysis
Blood samples collected in EDTA were taken im-
mediately before each infusion and then 24 hours after
the termination of therapy. The cells were stained
with the following combination of antibodies: (1)
IgG1 FITC / IgG1 PE / CD45 PerCP; (2) CD3
PerCP / CD8 FITC / CD4 PE; (3) CD45 PerCP /
CD3 FITC / CD16-CD56 PE; (4) CD45 PerCP /
CD3 FITC / CD19 PE; (5) CD45 PerCP / CD15
FITC / CD11b PE; (6) CD3 PerCP/anti-TCR--1
FITC /anti-TCR--1 PE; (7) CD3 PerCP/CD45RA
Table 1. Dose Escalation Plan*
Infusion
Day
Dose
Level 1
Dose
Level 2
Dose
Level 3
Dose
Level 4
1 6.25 50 400† 400
2 12.5 100 800 400
3 25 200 1600 400
4 50 400 3200 400
*Anti-CD45 dose, g/kg, represents the total of equivalent
amounts of each MAb.
†Maximum tolerated dose. Four patients (dose level 4) received
all of their infusions at this level.
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FITC/CD45RO PE; (8) CD45 PerCP/CD10 FITC/
CD22 PE; and (9) CD45 PerCP/anti-rat Ig FITC.
The red blood cells were lysed with FACS lysing
solution, and appropriate isotype controls were in-
cluded with each sample analysis. All antibodies were
purchased from BD Biosciences (Franklin Lakes, NJ).
Plasma Complement Measurement
Blood samples were taken before and immediately
after each infusion and again at 24 hours after an
infusion had been stopped. Levels of C3 and C4 in
sera were measured with a Behring (Marburg, Ger-
many) nephelometer.
Table 2. Characteristics of the Patient Population
UPN Diagnosis Sex
Age at
Diagnosis (y)
Age at
SCT (y)
Disease Status at
Transplantation
Other High-Risk
Features
Anti-CD45
Dose Levelj
Donor
HLA Match
J23 ALL M 2.9 4.1 Relapse 3 None 1 MUD 6/6
J31 MDS M 0.3 0.6 Primary refractory Monosomy 7 JMML 1 MUD 6/6
J44 ALL F 6.1 9.6 Relapse 3 None 1 MRD 6/6
J47 AML M 0.4 0.6 Primary refractory None 2 MRD 6/6
J54 AML M 2.7 3.8 Refractory relapse None 2 MMUD 5/6
J64 MDS M 1.8 3.4 Relapse 3 Prior allogeneic SCT 2 MRD 6/6
J68 ALL F 3.3 8.8 Relapse 3 Prior allogeneic SCT 2 MUD 6/6
J90 AML M 0.1 1.7 Relapse 2 Prior allogeneic SCT 3 MMRD 4/6
J222 ALL F 8.2 8.4 Remission 1 Prolonged induction 3 MRD 6/6
J223 AUL F 3.0 3.4 Remission 1 Biphenotypic leukemia 3 MUD 6/6
J230 MDS F 16.4 16.7 Primary refractory Monosomy 7 4 MMRD 5/6
J231 MDS M 6.4 7.4 Primary refractory Monosomy 7 4 MRD 6/6
J237 AML F 16.7 18.1 Refractory relapse None 4 MUD 6/6
J243 ALL F 0.3 2.2 Remission 2 Infant leukemia 4 MMUD 5/6
UPN
Preparative
Regimen
Stem Cell
Source GVHD Prevention
Days From Anti-
CD45 to Stem
Cell Preparative
Therapy
Days to
Engraftment Outcome Cause of Death
J23 AC/Cya/ATG/TBIb Marrow CSA/TCDf 2 11 A —
J31 Bu/Cyd/ATG Marrow CSA/TCDf 2 27 A —
J44 AC/Cya/TBIc Marrow Mtx/CSAg 10 20 240k Died of leukemia
J47 Bu/Cyd Marrow Mtx/CSAg 9 24 45k Died of leukemia
J54 AC/Cya/ATG/TBIb Marrow CSA/TCDf 2 15 19k Hemorrhage
J64 Bu/Cyd Marrow Mtx/CSAg 3 20 A —
J68 Bu/Cyd/ATG Marrow CSA/TCDf 3 NE 110k Multiorgan failure
J90 Fludarabine/
melphalane/ATG
Pharesis CD34
selection
Mtx/FK506h 2 27 135k Died of leukemia
J222 AC/Cya/TBIc Marrow Mtx/CSAg 3 18 A —
J223 AC/Cya/ATG/TBIb Marrow FK506/miniMtx/T&BCDi 3 15 A —
J230 AC/Cya/TBIb Pharesis CD34
selection
3 NE 0k Multiorgan failure
J231 AC/Cya/TBIc Marrow Mtx/CSAg 3 25 A —
J237 AC/Cya/TBIb Marrow FK506/miniMtx/T&BCDi 3 16 A —
J243 AC/Cya/TBIb Marrow FK506/miniMtx/T&BCDi 3 15 61k GVHD
UPN indicates unique patient number; JMML, juvenile myelomonocytic leukemia; MUD, matched unrelated donor; MRD, matched
related donor; MMUD, mismatched unrelated donor; MMRD, mismatched related donor; NE, no engraftment; A, alive and disease free.
aAC/Cy: cytarabine 3 g/m2 every 12 hours  6 on days 	8 to 	5; cyclophosphamide 45 mg/kg  2 on days 	7 and 	6.
bTBI (total body irradiation) 1440 cGy/8 fractions, 2 each on days 	4 to 	1.
cTBI (total body irradiation) 1200 cGy/8 fractions, 2 each on days	4 to	1. Other agents included cyclosporine andmethotrexate (BEAL); ATG
and cyclosporine, marrow T-cell depletion with anti-CD6 and anti-CD8 plus complement, and B-cell depletion with anti-CD20 (MISMUD-D);
ATG, FK506 and minimethotrexate (BEMUMID); CD34
 selective leukapharesis without additional GVHD preventive treatment (MOHEL).
dBu/Cy: busulphan 1 mg/kg/dose every 6 hours on days 	9 to 	6; cyclophosphamide (50 mg/kg/d on days 	5 to 	2).
eFludarabine (25 mg/m2 on days 	6 to 	2)/melphalan (90 mg/m2 on days 	3 and 	2).
fCSA/TCD: cyclosporine and T-cell depletion.
gMtx/CSA: methotrexate days 
1, 3, 6, and 12; cyclosporine.
hMtx/FK506: methotrexate days 
1, 3, 6, and 12; FK506.
iFK506/miniMtx/T&BCD: FK506; mini-methotrexate days 
1, 3, 6, and 11; T- and B-cell depletion.
jAnti-CD dose level: group 1 treated according to dose level 1 (Table 1); group 2 treated according to dose level 2; group 3 treated according
to dose level 3; group 4 treated according to dose level 4.
kDied; posttransplantation day of death.
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Pharmacokinetic Analysis
Blood was drawn before infusions and then at 15,
30, 60,120, 240, and 480 minutes after the ﬁrst infu-
sion. Samples were transported to the laboratory at
4°C within 1 hour of collection. Serum or plasma were
frozen at -80°C before analysis. Free CD45 MAb in
sera was assessed by measuring binding to Coulter
(Dallas, TX) Cyto-Trol Control Cells using a ﬂuores-
cein-labeled anti-rat IgG2b MAb (PharMingen, San
Diego, CA) and a BD Biosciences FACScan ﬂow cy-
tometer. Results were quantiﬁed by comparing bind-
ing levels in plasma with known amounts of the CD45
MAbs in equimolar amounts of sera.
The pharmacokinetics of free CD45MAb concen-
trations in sera were determined by ﬁtting a ﬁrst-order
1-compartment model to the data, using maximum
likelihood estimation as implemented by ADAPTII
software [15,16]. If an acceptable ﬁt to the data could
not be obtained with the 1-compartment model, non-
compartmental analysis was used. The highest con-
centration of free CD45 MAb (Cmax, ng/mL) was
deﬁned as the largest modeled concentration within
24 hours of the dose. For noncompartmental analyses,
the largest measured concentration within 24 hours of
the dose was used as the maximum concentration. The
area under the concentration-time curve from the
beginning of the infusion to 24 hours postinfusion
(AUC24, g/h/L) was deﬁned as the area under the
modeled curve. In noncompartmental analyses, it was
determined using a combination of linear and log
trapezoidal rules [17], where the linear trapezoidal
rule was used when concentrations were increasing or
steady and the log trapezoidal rule was used when the
concentrations were decreasing. In cases where the
free CD45 MAb concentration from a previous dose
did not return to predose levels at 24 hours, the
estimated AUC24- (based on the rate of elimination
determined from the terminal portion of the ﬁnal
dose) was subtracted from the AUC24 of the current
dose. Finally, systemic clearance (CL, L/h/kg) was
determined as ke*V, where ke (1/h) was the elimina-
tion rate constant and V (L/kg) the estimated volume
of distribution. In noncompartmental analyses, CL
was estimated as dose/AUC24.
Marrow Aspirates and Biopsies
All marrow samples were taken under local anesthe-
sia. Aspirates were stained and analyzed using standard
methods. Marrow biopsy specimens were decalciﬁed be-
fore sectioning and histopathologic examination.
Marrow Cultures
For patients receiving the ﬁxed dose of MAbs (400
g/kg), marrow aspirates were taken immediately be-
fore the infusions and within 24 hours of completion
of the 4-day course. Mononuclear cells (MNCs) were
prepared using Ficoll density centrifugation, and the
proportion of CD34
 cells present before and after
infusion was determined using a CD34 PE (BD Bio-
sciences) and ﬂow cytometric analysis. The number of
colony-forming units (CFUs) per 106 marrow MNCs
was assessed in conventional methylcellulose liquid
cultures, as previously described [18].
RESULTS
Toxicity
Mild systemic hypersensitivity reactions were the
principal toxicity accompanying the administration of
the CD45 MAb combination. There was no toxicity
encountered at the ﬁrst dose level, whereas at level 2,
1 of 3 patients developed fever with CD45 MAbs
administration. A second patient had a recurrent ve-
sicular eruption associated with herpes zoster infec-
tion, which had ﬁrst appeared before antibody ther-
apy. Three patients were treated at the third level of
dose escalation. On dose level 3 starting at 400 g/kg,
all patients developed fever, chills, or urticaria, which
were readily controlled with antipyretics and antihis-
tamines. By day 3, however, when the dose was 1600
g/kg, 2 of 3 patients developed bronchospasm, which
required administration of oxygen and epinephrine
and was considered the dose-limiting toxicity. There-
after, according to protocol, 4 additional patients re-
ceived anti-CD45 for 4 days at a daily ﬁxed dose of
400 g/kg (dosage group 4). Although 2 patients
treated at this dose developed mild urticaria and fever
(to 100°C), none had signiﬁcant respiratory symp-
toms, and all tolerated infusion without interruption.
Effects on Complement
Ex vivo studies showed that the YTH pair of
MAbs effectively ﬁxed human complement after bind-
ing to target cells [10,11]. We therefore measured C3
and C4 in sera before and immediately after infusion
of the MAbs. At dose levels 1 and 2, there were no
measurable changes in the levels of complement com-
ponents C3 and C4 (Figure 1A and 1C). However, a
signiﬁcant decrease in both C3 and C4 occurred in
patients receiving the third and fourth (ﬁxed) MAb
doses (Figure 1B and 1D).
Effects on Normal Lymphopoiesis and
Hemopoiesis
At dose levels 1 and 2, there were few changes in
the total WBC, neutrophil, and lymphocyte counts
(Figure 2A, 2B, and 2C). At dose level 3 and at the
ﬁxed dose of 400 g/kg, however, the decrease in
neutrophil and lymphocyte counts had become much
more pronounced and now persisted through treat-
ment with the CD45 MAb pair (Figure 2D, 2E, and
2F). More than a log reduction in the absolute neu-
R. A. Krance et al.
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trophil count was seen at the third and fourth (ﬁxed)
doses of CD45 MAbs, whereas the reduction in the
total leukocyte count and absolute lymphocyte count
approached 1 log. CD3
 T cells, CD20
 B cells, and
CD56
 NK cells all showed equivalent decreases
(data not shown). Platelets and red blood cells are
CD45-negative, and were unaffected by MAb infu-
sion.
Effects on Normal Myeloid Progenitor Cells
in Marrow
CD45 expression is lower on immature human
hemopoietic precursor cells than on their mature
progeny. Consistent with this observation, examina-
tion of marrow aspirates before and immediately after
treatment at the third and fourth (ﬁxed) doses of the
MAbs showed a doubling of the percentage of myeloid
precursor cells (promyelocytes, metamyelocytes, and
myelocytes), in treated marrow (Figure 3). We also
performed colony assays pretreatment and posttreat-
ment on the marrow MNCs of patients who had
received the fourth (ﬁxed) dose of CD45 MAb. There
was no obvious effect on the number or type of col-
onies formed: 150  18 (pretreatment) versus157 
28 (posttreatment), CFU per 106 marrow MNCs.
Pharmacokinetic Properties
A typical concentration-time proﬁle of free CD45
MAb, shown in Figure 4, indicates a serum half-life of
12 hours. The pharmacokinetic parameters for a 400
g/kg dose are summarized in Table 3. A dose 200
g/kg (approximately 60 g/h/L) was needed to ob-
tain a measurable AUC24 (Figure 5). Finally, at a dose
of 400 g/kg, there was a trend toward higher
CD45
 counts with a decreasing AUC24 (P  .01
based on the signiﬁcance of the slope of the linear
mixed-effects model) (Figure 6).
SCT Outcome
After completion of this CD45 MAb study, all
patients were able to proceed to their intended SCT,
Figure 1. (A-D) C3 and C4 complement levels in patients treated with CD45 Mabs. Complement C3 and C4 levels were measured (as
described in Patients, Materials, and Methods) immediately before infusions began (day 1) and then immediately at the termination of infusion
on days 2 to 4. There was a signiﬁcant decrease in C3 and C4 levels in patients in dose level groups 3 and 4 (ﬁxed dose). P  .01 for day 4
versus day 1 for C3 and P  .001 for day 4 versus day 1 for C4. Bars represent means and standard errors of the mean
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on standard institutional regimens (Table 2). Twelve
of the 14 patients engrafted between day 
11 and day

27 (median, day 
20), whereas 2 failed to engraft.
One of the patients with graft failure had MDS and
monosomy 7, and died on day 0 of multiple-organ
failure. At autopsy, the patient manifested multiple
constitutional organ abnormalities likely related to the
effects of in utero exposure to alcohol and other drugs.
The other child who failed to engraft had earlier
rejected two cord blood transplants. In December
2002, 7 patients were alive and disease free for 610 to
1555 days (median, 673 days). Seven patients have
died, 3 of recurrent or persistent disease, 1 of adeno-
virus hepatitis, 1 of aspergillosis, 1 of multiple-organ
failure, and 1 of unresponsive acute graft-versus-host
disease (GVHD).
DISCUSSION
This study shows that a dose of lytic CD45 MAb
pair that is well tolerated produces profound reduc-
tions in circulating lymphoid (T, NK, and B) and
myeloid cells, without producing marrow aplasia. This
nonmyeloablative, immunoreductive pattern is identi-
cal to that seen in our murine model [13], in which
these effects greatly facilitated engraftment of MHC
incompatible stem cells. The half-life of the CD45
antibodies in humans was12 hours, and nomeasurable
levels were present at the time of stem cell infusion.
Because CD45 expression increases with the stage
of hemopoietic maturity [19], the destruction of ma-
ture granulocytes and lymphocytes by CD45 MAbs
may be more evident than the ablation of hemopoietic
Figure 2. Total leukocyte (WBC), neutrophil, and lymphocyte counts/L in patients treated with CD45 MAbs. Cell counts were measured
preinfusion (day 1 to day 4). There were signiﬁcant decreases in leukocytes (days 3 and 4 versus day 2), neutrophils (days 3 and 4 versus day
2), and lymphocytes (days 2-4 versus day 1) for dosage groups 3 and 4 (ﬁxed), P  .001. Bars represent means and standard errors.
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progenitors. Nevertheless, such MAbs can be marrow
ablative in rats, producing lethal aplasia in the absence
of marrow rescue [12]. This ﬁnding contrasts sharply
with results of the present clinical study, in which
ablation did not occur at tolerated doses of the MAb
pair. On the contrary, we detected an increased pro-
portion of myeloid precursor cells and unchanged
numbers of myeloid CFUs in marrow, even at a time
when the mature progeny of these cells had largely
disappeared. These data are identical to those ob-
tained in mice given saturating quantities of lytic
CD45 Mab [13].
In mice, myelodepletion is transient [13]. Because
the patients in our study went on to receive ablative
preparative regimens, we do not know if the effects on
the myeloid series in humans is transient. Preliminary
data from our studies coupling CD45 MAbs with
subablative regimens suggest that the pattern of my-
eloablation will be similar to that seen in mice.
The CD45 rat IgG2b MAb pair act synergistically
to recruit host lytic mechanisms (complement-medi-
ated and cell-mediated) [10,11]. The pharmacody-
namic relationship of MAb dose to total leukocyte
count and the pharmacokinetic correlation of AUC24
with numbers of circulating CD45
 cells both indi-
cate that the MAb depleted normal leukocyte counts
in a dose- dependent manner. In vitro, the CD45
MAb pair can deplete cells by complement-mediated
lysis once MAb levels increase to100 g/mL. These
concentrations were achieved in our in vivo study at all
but the lowest MAb doses, and a contribution from
complement-mediated lysis to the depletion of leuko-
cytes is suggested by the decomplementing effects of
high doses of MAb. However, as a contiguous pair on
target leucocytes, the rat IgG2b MAb pair also can
efﬁciently bind to human Fc receptors on ﬁxed tissue
macrophages and on circulating monocytes/NK cells,
permitting opsonization and antibody-dependent cell-
mediated cytotoxicity, respectively [20]. In vitro, these
cell-dependent clearance mechanisms may operate at
lower concentrations of the antibody (25 g/mL)
than complement-mediated lysis (100 g/mL)
[11,20], restricting their most important contribution
Table 3. Pharmacokinetic Parameters of CD45 Disposition
Dose (400 g/kg) Median 1st Quartile 3rd Quartile
AUC (g/h/L) 1438.2 182.1 7570.5
Cmax (ng/mL) 411.1 62.4 1232.6
CL (L/h/kg) 0.28 0.053 2.20
AUC indicates area under the concentration-time curve from
the beginning of the infusion to 24 hours after infusion; Cmax,
largest modeled concentration of free anti-CD45 within 24 hours of
the dose administration; CL, systemic clearance of anti-CD45 was
determined as ke*V, where ke (1/h) was the elimination rate con-
stant and V (L/kg) the estimated volume of distribution.
Figure 3. Percentage of myeloid precursors and mature myeloid elements in marrow smears before and after therapy. The percentage of
myeloid precursors (promyelocytes, metamyelocytes, and myelocytes) were signiﬁcantly increased in posttherapy groups 3 and 4 (ﬁxed dose),
P  .03. Bars represent means and standard errors.
Figure 4. Unbound CD45 concentration-time proﬁle in plasma.
Plasma was obtained preinfusion and at 15, 30, 60, 120, 240, and
480 minutes after infusion. The free CD45 assay and pharmacoki-
netic analyses are described in Patients, Materials, and Methods.
Each component of the ﬁgure illustrates the concentration-time
gradient at the MAb doses shown (400-3200 g/kg). The lines
are simulated concentrations from the pharmacokinetic model
parameters.
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to cell-mediated lysis to the beginning of the infusion
and the period after its termination, when MAb con-
centrations are lower. Beyond these lytic mechanisms,
it should be noted that CD45 MAbs also interfere
with the tyrosine phosphatase activity of the target
molecule [21] to induce T-cell hyporesponsiveness,
leading to reduced activation of both mitogens and
antigens, including alloantigens [10,22,23]. Hypore-
sponsiveness persists for several days, but the impor-
tance of this additional immunosuppressive mecha-
nism to the overall effects induced by the MAb pair
remains unknown.
Our pharmacokinetic analysis relied on measure-
ment of total anti-CD45 activity in serum, therefore,
we were unable to assess the individual pharmacoki-
netic properties of the 2 rat CD45 MAb clones (YTH
24 and YTH54). Because both antibodies share the
same rat IgG2b isotype, and both are directed against
contiguous epitopes on the same target molecule [11],
it is likely that their pharmacokinetics are similar. But,
even if they are distinct, our analysis indicates that a
total MAb dose 200 g/kg/d (ie, 100 g/kg/d of
each antibody) is required to secure an AUC24 asso-
ciated with biologically active levels of MAbs. Such
doses were well tolerated in the present study, at least
to a level of 400 g/kg/d. Figure 4 and Table 3 also
show that free MAb is rapidly cleared from the circu-
lation once the infusion is terminated. Hence, MAb
administration early during delivery of the preparative
regimen allows full clearance of the antibody by the
time of marrow infusion. This rapid clearance means
that the MAb will produce effects only on the host
immune system, allowing the donor stem cell product
either to retain donor T cells (and any graft-versus-
leukemia activity these cells may possess) or to be
independently and discretely manipulated [24-27].
How may lytic CD45 MAb be incorporated into
human SCT? The absence of myeloablation indicates
that their primary contribution may be in nonmyelo-
ablative transplantation. Because CD45 MAbs cytore-
duce all lymphoid subsets, including T and NK cells,
the perturbation of the immune system they produce
may be more extensive than that achieved with other
MAbs directed to fewer cellular components. In the
HLA mismatched setting, in particular, NK cells have
been shown to be of signiﬁcant importance in medi-
ating the rejection mechanism in rodents and in hu-
mans [28,29]. Certainly in our murine model, CD45
MAb alone facilitated engraftment between H2 fully
mismatched donors and recipients, an effect that could
not be reproduced by antibodies to T or NK cells [13].
Hence, there may be value in exploring the use of
these MAbs in HLA mismatched transplantation, par-
ticularly for patients with nonmalignant disease,
where exposure to chemotherapeutic agents and to
radiation is least desirable.
A second potential application for these CD45
MAbs is to enhance the antileukemic activity of SCT
becaue they also bind to leukemic blasts. In this study,
3 patients had measurable numbers of blasts in mar-
row before MAb infusion. In 2 patients (J47 and J54),
there was a reduction in the proportion of leukemic
cells posttreatment (from 22% and 18% to 5%).
However, in patient J23 (ALL, treated at dose level 1),
the percentage of blasts remained 70%. If this sec-
ondary effect is conﬁrmed in a larger series, CD45
Figure 5. MAb dose versus AUC. The AUC24 for each MAb dose
in each patient was used to assess the relationship between the dose
of antibody infused and the maintenance of an AUC24 above base-
line values. A minimum dose of 200 g/kg is required to ensure a
measurable AUC24.
Figure 6. AUC versus CD45
 cell count at a MAb dose of 400
g/kg. Each symbol represents an individual patient’s CD45
 cell
count in peripheral blood and the corresponding AUC24 (g/h/L)
for that patient. The ﬁgure shows the relationship between AUC24
and CD45
 cell counts, such that a higher AUC24 is associated with
lower counts.
R. A. Krance et al.
280
MAb also may be a useful addition to the treatment of
malignant disease by conventional myeloablative SCT
because they did not appear to add to the toxicity of
the procedure.
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